Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
| ▸ | CBS | P35520 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735665 | 0.98 | BLM (0.33) | ALDH1A1MEN1KMT2ABLMLMNA | |
| SCHEMBL18752950 | 0.88 | CA12 (0.37) | ALDH1A1PTGS2CA12CA1CA2 | |
| SCHEMBL397067 | 0.81 | BLM (0.41) | ALDH1A1MEN1KMT2ABLMLMNA | |
| SCHEMBL2232094 | 0.81 | BLM (0.41) | ALDH1A1MEN1KMT2ABLMLMNA | |
| SCHEMBL456770 | 0.79 | — | — | |
| SCHEMBL437092 | 0.78 | ALDH1A1 (0.46) | ALDH1A1PTGS1PTGS2CA12CA1 | |
| SCHEMBL28277555 | 0.78 | ALDH1A1 (0.46) | ALDH1A1PTGS1PTGS2CA12CA1 | |
| SCHEMBL439675 | 0.78 | ALDH1A1 (0.46) | ALDH1A1PTGS1PTGS2CA12CA1 | |
| SCHEMBL11792981 | 0.78 | ALDH1A1 (0.46) | ALDH1A1PTGS1PTGS2CA12CA1 | |
| SCHEMBL1773954 | 0.78 | ALDH1A1 (0.46) | ALDH1A1PTGS1PTGS2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116456963-A | NO-PDE5 inhibitors for the treatment of dry age-related macular degeneration, geographic atrophy and glaucoma-related neurodegeneration | 尼科斯股份有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-112566670-A | Nitric oxide releasing phosphodiesterase type 5 inhibitors | 尼科斯股份有限公司 | 2021-03-26 | — | — | CN | claimed |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2024-07-25 | — | — | US | disclosed |
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | NICOX S.A. (FR) | 2024-05-14 | — | — | US | disclosed |
| CN-116456963-A | NO-PDE5 inhibitors for the treatment of dry age-related macular degeneration, geographic atrophy and glaucoma-related neurodegeneration | 尼科斯股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2021-10-21 | — | — | US | disclosed |
| EP-3833395-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | Nicox S.A. (FR) | 2021-06-16 | — | — | EP | disclosed |
| CN-112566670-A | Nitric oxide releasing phosphodiesterase type 5 inhibitors | 尼科斯股份有限公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2020030489-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2020-02-13 | — | — | WO | disclosed |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | NICOX S.A. (FR) | 2019-05-07 | — | — | US | disclosed |
| US-20170291920-A1 | NITRIC OXIDE DONATING CARNOSINE COMPOUNDS | NICOX SA (FR) | 2017-10-12 | — | — | US | disclosed |
| EP-2993172-B1 | Nitric oxide donating carnosine compounds | NICOX SCIENCE IRELAND (IE) | 2017-04-19 | — | — | EP | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| WO-2016155906-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | NICOX S.A. (FR) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016034619-A1 | NITRIC OXIDE DONATING CARNOSINE COMPOUNDS | NICOX SCIENCE IRELAND (IE) | 2016-03-10 | — | — | WO | disclosed |
| EP-2993172-A1 | Nitric oxide donating carnosine compounds | Nicox Science Ireland (IE) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015109011-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2011101245-A1 | NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPATHIC PAIN | NICOX S.A. (FR) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011092065-A1 | NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPHATIC PAIN | NICOX S.A. (FR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | PDE5A, PDE3A, PDE3B | ALDH1A1 677/4885MEN1 2507/4885KMT2A 3864/4885 |
| US-20170291920-A1 | NITRIC OXIDE DONATING CARNOSINE COMPOUNDS | NOS1, NOS2, NOS3 | ALDH1A1 1017/4885MEN1 889/4885KMT2A 2668/4885 |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | NOS1, NOS2, NOS3 | ALDH1A1 580/4885MEN1 1685/4885KMT2A 3994/4885 |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | PTGIS, NOS2, PTGIR | ALDH1A1 584/4885MEN1 3031/4885KMT2A 4013/4885 |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE6A, PDE3A | ALDH1A1 397/4885MEN1 3947/4885KMT2A 4280/4885 |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE3A, PDE6A | ALDH1A1 397/4885MEN1 4079/4885KMT2A 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.